Video

The Importance of Antigen Loss in R/R Disease

Author(s):

Stephen J. Schuster, MD, Abramson Cancer Center,Caron A. Jacobson, MD, Dana-Farber Cancer Institute

Related Videos
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Amitkumar Mehta, MD
Jasmin M. Zain, MD
Marco Davila, MD, PhD
Sattva S. Neelapu, MD
James Ignatz-Hoover, MD, PhD
Sundar Jagannath, MBBS
Related Content
Chad Williams, PhD
November 11th 2024

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
October 10th 2022

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

FDA
November 8th 2024

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 28th 2022

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

FDA
October 31st 2024

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.
October 29th 2024

The Future of Hematologic Cancer Care Shifts Toward Personalized and Chemotherapy-Free Regimens